Liminal BioSciences
QC - Laval
BiotechnologyFocus: Small Molecules, Biologics, Protein Technologies
Liminal BioSciences is a life sciences company focused on Small Molecules, Biologics, Protein Technologies.
Metabolic DiseasesRare DiseasesRespiratory
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Fezagepras
HyperammonemiaClinical Trials (1)
NCT05349435A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
Phase 1PBI-4050 and midazolam
HealthyClinical Trials (1)
NCT03637049Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects
Phase 1PBI-4547
Healthy SubjectsClinical Trials (1)
NCT04068259Single Ascending Dose Study of PBI-4547 in Healthy Subjects
Phase 1PBI-4050/ Placebo
FibrosisClinical Trials (1)
NCT04695041A Healthy Volunteer Study of PBI-4050
Phase 1Phase 2
Clinical Trials (1)
NCT02538536A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2PBI4050
Cystic FibrosisClinical Trials (1)
NCT02955888Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Phase 2PBI-4050
Inflammation and FibrosisClinical Trials (1)
NCT02739217Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
Phase 2PBI-4050
Type 2 Diabetes MellitusClinical Trials (1)
NCT03081598Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
Phase 2PBI4050
Type 2 DiabetesClinical Trials (1)
NCT02562573Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
Phase 2PBI-4050
Alström SyndromeClinical Trials (1)
NCT03184584Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Phase 2/3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 10 clinical trials